Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.

Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, Heinig S, Hoffmann E, Wegge T, Krusch M, Faltinger F, Killian S, Sprogoe K, Karpf DB, Breinholt VM, Cleemann F.

J Bone Miner Res. 2019 Nov;34(11):2075-2086. doi: 10.1002/jbmr.3824. Epub 2019 Oct 9.

PMID:
31291476
2.

The CD95/CD95L pathway is involved in phagocytosis-induced cell death of monocytes and may account for sustained inflammation in neonates.

Gille C, Dreschers S, Leiber A, Lepiorz F, Krusch M, Grosse-Opphoff J, Spring B, Haas M, Urschitz M, Poets CF, Orlikowsky TW.

Pediatr Res. 2013 Apr;73(4 Pt 1):402-8. doi: 10.1038/pr.2012.196. Epub 2012 Dec 26.

PMID:
23269121
3.

Effects of BCR-ABL inhibitors on anti-tumor immunity.

Krusch M, Salih HR.

Curr Med Chem. 2011;18(34):5174-84. Review.

PMID:
22087818
4.

Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation.

Schmiedel BJ, Arélin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR.

Int J Cancer. 2011 Jun 15;128(12):2911-22. doi: 10.1002/ijc.25635. Epub 2010 Oct 19.

5.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M.

Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233.

6.

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR.

Blood. 2010 Apr 15;115(15):3058-69. doi: 10.1182/blood-2009-06-227934. Epub 2009 Dec 14. Erratum in: Blood. 2010 Dec 23;116(26):6152.

PMID:
20008791
7.

The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.

Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, Salih HR.

J Immunol. 2009 Dec 15;183(12):8286-94. doi: 10.4049/jimmunol.0902404.

8.

Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.

Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM, Salih HR.

Cancer Res. 2009 Feb 1;69(3):1037-45. doi: 10.1158/0008-5472.CAN-08-2650. Epub 2009 Jan 20.

9.

Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.

Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR.

J Immunol. 2008 Nov 15;181(10):6711-9.

10.

Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity.

Baltz KM, Krusch M, Baessler T, Schmiedel BJ, Bringmann A, Brossart P, Salih HR.

Blood. 2008 Nov 1;112(9):3735-43. doi: 10.1182/blood-2008-03-143016. Epub 2008 Aug 8.

PMID:
18689545
11.

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR.

Clin Cancer Res. 2008 Jun 1;14(11):3520-8. doi: 10.1158/1078-0432.CCR-07-4744.

12.

Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions.

Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, Radsak MP, Rammensee HG, Salih HR.

FASEB J. 2007 Aug;21(10):2442-54. Epub 2007 Mar 14.

PMID:
17360848
13.

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF.

Blood. 2007 Jun 1;109(11):4816-24. Epub 2007 Mar 6.

14.

Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.

Hentschel N, Krusch M, Kiener PA, Kolb HJ, Salih HR, Schmetzer HM.

Eur J Haematol. 2006 Aug;77(2):91-101. Epub 2006 Jun 23.

PMID:
16800841
15.

The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans.

Salih HR, Wintterle S, Krusch M, Kroner A, Huang YH, Chen L, Wiendl H.

Exp Hematol. 2006 Jul;34(7):888-94.

PMID:
16797416
16.

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR.

Cancer Res. 2005 Jul 15;65(14):6321-9.

Supplemental Content

Loading ...
Support Center